Oral dissolving strips for the delivery of isoniazid in children and adults
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN272201600033C
- Awardee
-
Oak Therapeutics Inc. UEI SJ7GGFACQTJ5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $220,582
Award facts
- Opportunity
-
- PHS20161 Solicitation number
- A solicitation of the national institutes of health (NIH) and the centers for disease Award Notice · Posted Sep 19, 2016
- Contract value 100% obligated
- $220,582.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 5 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Oxnard, CA 93033, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Clinger-Cohen Act FAR part 39
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Original award | $220,582 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded a $220,582 Small Business Innovation Research (SBIR) Phase I contract to Oak Therapeutics Inc., a pharmaceutical company based in Westlake Village, California. The contract is for the development of oral dissolving strips for the delivery of isoniazid, a medication used to treat tuberculosis, in children and adults. This contract is a Firm Fixed Price definitive contract, set aside for total small business participation. Oak Therapeutics has previously received NIAID grant funding to develop oral dissolvable formulations for other difficult-to-treat conditions, including latent tuberculosis and pediatric HIV.
Quick answers
Who was awarded contract HHSN272201600033C?
HHSN272201600033C was awarded to Oak Therapeutics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 24, 2016.
How much is contract HHSN272201600033C worth?
The government has obligated $220,582 on HHSN272201600033C.
Was contract HHSN272201600033C competed?
The extent of competition for HHSN272201600033C was full and open competition after exclusion of sources. The government received 5 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award